BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 37958702)

  • 1. Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.
    Serioli S; Agostini L; Pietrantoni A; Valeri F; Costanza F; Chiloiro S; Buffoli B; Piazza A; Poliani PL; Peris-Celda M; Iavarone F; Gaudino S; Gessi M; Schinzari G; Mattogno PP; Giampietro A; De Marinis L; Pontecorvi A; Fontanella MM; Lauretti L; Rindi G; Olivi A; Bianchi A; Doglietto F
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.
    Wang L; Wei C; Wang Y; Huang N; Zhang T; Dai Y; Xue L; Lin S; Wu ZB
    Front Endocrinol (Lausanne); 2023; 14():1149997. PubMed ID: 37534217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.
    Zhou Y; Zhang A; Fang C; Yuan L; Shao A; Xu Y; Zhou D
    CNS Neurosci Ther; 2023 Oct; 29(10):2744-2759. PubMed ID: 37341156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
    Wen S; Li J; Yang J; Li B; Li N; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors.
    Guo X; Yang Y; Qian Z; Chang M; Zhao Y; Ma W; Wang Y; Xing B
    Cancer Lett; 2024 Jun; 592():216908. PubMed ID: 38677640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of biomarkers associated with the invasion of nonfunctional pituitary neuroendocrine tumors based on the immune microenvironment.
    Wu J; Guo J; Fang Q; Liu Y; Li C; Xie W; Zhang Y
    Front Endocrinol (Lausanne); 2023; 14():1131693. PubMed ID: 37522128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients.
    Guaraldi F; Morandi L; Zoli M; Mazzatenta D; Righi A; Evangelisti S; Ambrosi F; Tonon C; Giannini C; Lloyd RV; Asioli S
    Clin Endocrinol (Oxf); 2022 Dec; 97(6):763-772. PubMed ID: 36161330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive nonfunctioning pituitary neuroendocrine tumors.
    Portovedo S; Neto LV; Soares P; Carvalho DP; Takiya CM; Miranda-Alves L
    Brain Tumor Pathol; 2022 Oct; 39(4):183-199. PubMed ID: 35725837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
    Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
    Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
    Luo M; Tang R; Wang H
    J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
    Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
    Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive pituitary tumors (PitNETs).
    Nishioka H
    Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
    Spada A; Mantovani G; Lania AG; Treppiedi D; Mangili F; Catalano R; Carosi G; Sala E; Peverelli E
    Neuroendocrinology; 2022; 112(1):15-33. PubMed ID: 33524974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of cholesterol metabolism-related subtypes in nonfunctioning pituitary neuroendocrine tumors and analysis of immune infiltration.
    Feng T; Hou P; Mu S; Fang Y; Li X; Li Z; Wang D; Chen L; Lu L; Lin K; Wang S
    Lipids Health Dis; 2023 Aug; 22(1):127. PubMed ID: 37563740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors.
    Yan N; Xie W; Wang D; Fang Q; Guo J; Chen Y; Li X; Gong L; Wang J; Guo W; Zhang X; Zhang Y; Gu J; Li C
    Genome Med; 2024 Jan; 16(1):2. PubMed ID: 38167466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.
    García-Martínez A; Sottile J; Sánchez-Tejada L; Fajardo C; Cámara R; Lamas C; Barberá VM; Picó A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1272-1282. PubMed ID: 30423170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
    Luo P; Zhang L; Yang L; An Z; Tan H
    Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion.
    Principe M; Chanal M; Ilie MD; Ziverec A; Vasiljevic A; Jouanneau E; Hennino A; Raverot G; Bertolino P
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.